

4 April 2017

OBJ to commence pharmaceutical clinical trial for BodyGuard technology

OBJ Limited (ASX: OBJ) is pleased to report that the Commonwealth Government has agreed to assist funding of a trial to examine the efficacy of OBJ's BodyGuard polymer hydro-array technology in delivering the therapeutic anti-inflammatory drug Ibuprofen, also known as IBU.

It will be OBJ's first pharmaceutical clinical trial being conducted under the Innovation Connections Grant Scheme in conjunction with Curtin University.

The project is budgeted to cost approximately \$87,000 with the Government funding 50% of this amount.

The clinical study protocol was developed in consultation with a major US pharmaceutical and healthcare company and will be conducted by Professor Tony Wright of the Curtin University School of Physiotherapy.

This cornerstone study is expected to demonstrate the benefits of the BodyGuard technology over traditional drug-in-adhesive systems for the delivery of topical pharmaceutical agents.

The BodyGuard program seeks to develop a wide range of products to service multiple market sectors in the joint pain management and healthy aging sectors. The clinical trial performed at the University of Queensland in 2016 proved the efficacy and consumer acceptance of the first BodyGuard product against commonly available NSAIDs.

OBJ's Lubricen formulation is directed at the non-NSAID markets and management is working with several companies to distribute BodyGuard with this formulation. Undertaking the IBU clinical trial opens up a broader market where immediate pain relief is required, an area in which many of the multinational pharmaceutical companies operate.

With the aid of its USA pharmaceutical partner, OBJ has succeeded in developing a new topical formulation and array combination that has shown, in laboratory studies, to be very effective at delivering IBU through the skin.

The Curtin study, with the support of the Innovation Connections Grant Scheme, will test the new formulation and format in a double blind clinical efficacy study. A successful outcome will not only support the OBJ technology as a suitable IBU delivery development platform for its partners, but will also demonstrate the power of the OBJ polymer hydro-array technology for use with many other drugs not currently well served by traditional drug-in-adhesive product approaches.

Directors

Mr Glyn Denison
Mr Jeffrey Edwards
Dr Chris Quirk

Company Secretary

Mr John Palermo

Registered Office:

284 Oxford Street
Leederville
Western Australia 6007
Tel: +61 8 9443 3011
Fax: +61 8 9443 9960
www.obj.com.au
ABN: 72 056 482 636

For personal use only

4 April 2017

About OBJ

OBJ develops proprietary magnetic micro-array drug delivery and product enhancement technologies for the pharmaceutical, healthcare and consumer goods sectors. OBJ partners companies in the design and development of next generation products using physical science rather than chemistry to provide new levels of product performance without the cost of reformulation or new ingredient approvals.

OBJ offers a portfolio of proprietary technologies and supports partners by providing IP-protected market exclusivity, expertise in magnetic array design, feasibility and efficacy and claims testing, engineering and production.

About OBJ's technologies

OBJ has developed a number of physical enhancement technologies based on the interactions between ingredient molecules and weak atomic forces. These influence the movement and penetration through the skin of drugs, active ingredients and formulations at the molecular level.

Complex 3-D magnetic fields produced by low cost microarrays or powdered electromagnetic inductors have the ability to repulse certain molecules to enhance diffusion and to alter the permeability of biological and non-biological targets.

OBJ's low cost micro-array film technology that utilise diamagnetic repulsion, induced permeation and energy redirection has already reached international markets to provide OBJ's Partners with a new way of managing the speed, depth of penetration and delivery of active ingredients in a wide range of pharmaceutical, healthcare and consumer products.

Forward-looking statements

This announcement contains certain "forward-looking statements" concerning OBJ. Where OBJ expresses or implies an expectation or belief as to future events or results, such expectation or belief is expressed in good faith and believed to have a reasonable basis.

Forward-looking statements provided in this announcement are based on assumptions and contingencies which are subject to change without notice. Such forward-looking statements including statements regarding intentions, planned events and potential results are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance.

There can be no assurance that actual outcomes will not differ materially from these forward-looking statements, and there are risks associated with OBJ and the industry which may affect the accuracy of the forward-looking statements. OBJ does not undertake any obligation to release publicly any revisions to any forward looking statement to reflect events or circumstances after the date of this announcement or to reflect the occurrence of unanticipated events, except as may be required under applicable securities laws.



OBJ RELEASE

4 April 2017

For more information:

Matthew Wright

matt@nwrcommunications.com.au

Phone: +61 451 896 420

For personal use only

Registered Office:

**284 Oxford Street
Leederville**

Western Australia 6007

Tel: +61 8 9443 3011

Fax: +61 8 9443 9960

www.obj.com.au

ABN: 72 056 482 636